FMFlorence Moulin

Florence Moulin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Florence Moulin has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Scemla

    Service de Néphrologie - Transplantation, Hôpital Necker-Enfants malades, Groupe hospitalier AP-HP.Centre - Université Paris Cité, Paris, France; RTRS Centaure, Labex Transplantex, Université Paris Cité, France

    2 shared publications
  • Julie Toubiana

    Service Pédiatrie Générale et Maladies Infectieuses, Hôpital Necker-Enfants malades, AP-HP, Université Paris Cité

    2 shared publications
  • Mehdi Oualha

    Pediatric Intensive Care Unit, Necker Hospital, APHP, Centre - Paris University, Paris, France

    2 shared publications
  • Michael Levy

    Department of Surgical Intermediate Care, Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France

    2 shared publications
  • Pierre Frange

    Microbiology department, Necker-Enfants malades Hospital, AP-HP, Université Paris Cité, Paris, France; Université Paris Cité, URP 7328 FETUS, Paris, France

    2 shared publications
  • Sylvain Renolleau

    Réanimation Et Surveillance Continue Médico-Chirurgicales Pédiatriques, Hôpital Necker-Enfants Malades, AP-HP, Université de Paris, Paris, France

    2 shared publications

Latest Publications

  • No durable impact of COVID-19 measures on the hospital burden of respiratory syncytial virus (France, 2018–2022)

    by Jacques Fourgeaud, Julie Toubiana, Hélène Chappuy, Christophe Delacourt, Florence Moulin, Perrine Parize, Anne Scemla, Hanene Abid, Marianne Leruez-Ville, Pierre Frange


  • Assessment of the Effects of a High Amikacin Dose on Plasma Peak Concentration in Critically Ill Children

    by Rym Medjebeur Hanna, Michael Levy, Emmanuelle Bille, Carole Hennequin, Fabrice Lesage, Jérôme Naudin, Florence Moulin, Marie Blanquer, Agathe Béranger, Sylvain Renolleau, et al.

    Objectives This study aimed to assess the incidence of amikacin plasma peak concentration (Cmax) below 60 mg·L−1 in critically ill children receiving an amikacin dosing regimen of 30 mg kg−1·day−1. Secondary objectives were to identify factors associated with low Cmax and to assess the incidence of acute kidney injury (AKI). Methods A retrospective observational study was performed in two French pediatric intensive care units. All admitted children who received 30 mg·kg−1 amikacin and had a Cmax measurement were eligible. Clinical and biological data, amikacin dose, and concentrations were collected. Results In total, 30 patients were included, aged from 3 weeks to 7 years. They received a median amikacin dosage of 30 mg kg−1·day−1 (range 29–33) based on admission body weight (BW), corresponding to 27 mg kg−1·day−1 (range 24–30) based on actual BW. Cmax was < 60 mg·L−1 in 21 (70%) children and none had a Cmax ≥ 80 mg·L−1. Among the 15 patients with a measured minimum inhibitory concentration (MIC), 13 (87%) had a Cmax/MIC ratio > 8. Univariate analysis showed that factors associated with Cmax < 60 mg·L−1 were high estimated glomerular filtration rate (p = 0.015) and low blood urea concentration (p = 0.001). AKI progression or occurrence was observed after amikacin administration in two (7%) and six (21%) patients, respectively. Conclusions Despite the administration of the maximal recommended amikacin dose, Cmax was below the pharmacokinetic target in 70% of our pediatric population. Further studies are needed to develop a pharmacokinetic model in a population of critically ill children to optimize target attainment.


  • Open Access

    Le SARS-CoV-2 en réanimation pédiatrique

    by Mehdi Oualha, Arnaud Wiedemann, Michael Levy, Noémie Vanel, Florence Moulin, Laure De Saint Blanquat, Maryline Chomton, Sylvain Renolleau, Anne-Sophie Guilbert, Etienne Javouhey

    In a lesser extent than adults Intensive Care Units (ICUs), Pediatric ICUs (PICUs) had to deal with the SARS-CoV-2 pandemic. Pediatric intensivists managed serious pediatric forms of primary infections and then in a second stage, post-infectious systemic inflammatory attacks. Some of them helped with the management of adults with a severe form of SARS-CoV-2. Therefore, they had to adapt in record time. In this review, we report (i) the literature data on these two severe pediatric forms, the primary infection and the systemic inflammatory manifestations associated with SARS-CoV-2; (ii) the experience of PICUs in the management of critically ill adults with SARS-CoV-2 infection and (iii) and the impact of the pandemic on the place of families of children in critical situation in PICUs.

  • Open Access

    Preventing respiratory syncytial virus infections in hospitalized children and adults: should we do better?

    by Pierre Frange, Julie Toubiana, Perrine Parize, Florence Moulin, Anne Scemla, Marianne Leruez-Ville


  • The burden of respiratory viral disease in hospitalized children in Paris

    by Marie-Joelle El-Hajje, Cecile Lambe, Florence Moulin, Nathalie de Suremain, Charlotte Pons-Catalano, Martin Chalumeau, Josette Raymond, Pierre Lebon, Dominique Gendrel

    A virus was identified in 464 out of 1,212 patients, 8 days to 16 years of age, who were admitted to the hospital in Paris during a 3 year period. Respiratory syncytial virus (RSV) was found in 428 patients, 74% were younger than 6 months with bronchiolitis, and 6% were older than 2 years. RSV was the first virus isolated in all patients and in those with pneumonia or asthma. The low number of admissions due to parainfluenzae viruses is characteristic of this area compared to other countries.